SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
SGNT was delisted on the 29th of August, 2016.
136 hedge funds and large institutions have $395M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2016 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 33 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
88% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 33
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
1% more funds holding
Funds holding: 134 → 136 (+2)
5% less capital invested
Capital invested by funds: $418M → $395M (-$22.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$16.7M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$9.69M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.04M |
| 4 |
Bank of New York Mellon
New York
|
+$6.24M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$4.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$27.8M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$17.1M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$7.16M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$7.01M |
| 5 |
Millennium Management
New York
|
-$5.28M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCMH
151
Cornerstone Capital Management Holdings
New York
| – | -$121K | -7,600 | Closed |
|
|
PAM
152
Panagora Asset Management
Boston,
Massachusetts
| – | -$13K | -802 | Closed |
|
153
Loomis, Sayles & Company
Boston,
Massachusetts
| – | -$9K | -568 | Closed |
|
|
KC
154
Kingfisher Capital
Charlotte,
North Carolina
| – | -$5K | -298 | Closed |
|
|
PSC
155
Piper Sandler & Co
Minneapolis,
Minnesota
| – | -$3K | -185 | Closed |
|
SGNT Hedge Fund Activity: Q1 2016 in Review
136 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q1 2016, worth a combined $395M — down 5.3% from $418M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SGNT positions and 19 closed out — a net gain of 3 holders — while 62 added to existing stakes and 33 trimmed.
The largest buyer was Carlson Capital, opening a new position worth an estimated $16.7M. The largest seller was HealthCor Management, exiting entirely with an estimated $27.8M sold.
- 136 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q1 2016, up from 134 in Q4 2015.
- Funds reported $395M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q1 2016, down 5.3% quarter-over-quarter.
- 22 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q1 2016 and 19 closed out, a net change of +3 holders.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q1 2016 was Carlson Capital, an estimated $16.7M added.
- The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q1 2016 was HealthCor Management, an estimated $27.8M sold.
Based on aggregated 13F filings for Q1 2016.